drugset / Trial / NCT00109668

Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids

NCT00109668

Phase 3 Completed 415 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

QVAR in a standard press and breath inhaler (QVAR-MDI) has been approved by the Food and Drug Administration (FDA) for use in the United States. The purpose of this study is to determine the level of asthma control when comparing the safety and effectiveness of QVAR in two different devices, a metered dose inhaler (MDI) and a breath operated inhaler (BOI).

Timeline

Start
2004-07-31
Primary completion
2006-09-30
Completion
2006-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject beclomethasone dipropionate Other / unclassified Inhaled

Indications